Ideal body weight (IBW) and adjusted body weight (AdjBW) are different dosing-weight tools. The Devine IBW equations are associated with Ben J. Devine. IBW estimates a height-based reference weight; AdjBW starts with IBW and adds a defined fraction of the difference between actual and ideal weight. Neither should automatically replace actual body weight for every medicine.
IBW and AdjBW at a glance
Ideal body weight
- Usually based on height and sex-specific formula constants.
- Does not directly include the patient's actual body mass.
- Can be used by medicine-specific dosing references or other clinical calculations.
Adjusted body weight
- Combines IBW with part of the excess above IBW.
- Requires a correction factor, often written as a fraction such as 0.4.
- Is used only where a medicine-specific source or protocol calls for it.
Why do different dosing weights exist?
In obesity, body composition changes do not affect the distribution and clearance of every medicine in the same way. Some medicines distribute substantially into adipose tissue; others do not. Renal clearance, lean mass and other pharmacokinetic factors can also change. That is why a single universal body-weight rule cannot safely be applied to all weight-based dosing.
What does adjusted body weight try to do?
AdjBW is a compromise between actual body weight and IBW. A common form is:
A 0.4 factor means 40% of the difference between actual weight and IBW is added back to IBW. That factor is not a biological constant that should be applied to every medicine. It comes from medicine- and population-specific dosing approaches.
Which weight should you use for a medication dose?
Use the dosing weight specified by the medicine reference, product information, pharmacist instruction or local protocol.
Do not choose IBW or AdjBW simply because the patient has obesity. Different medicines can require total, ideal, adjusted or another weight descriptor.
ZEMDRI (plazomicin) labeling is a particularly clear example: it uses adjusted body weight when total body weight is at least 25% above IBW and explicitly defines AdjBW = IBW + 0.4 × (TBW − IBW). UCSF, by contrast, uses >120% of IBW for multiple antimicrobials. The different thresholds reinforce the same rule: the governing source decides when and how AdjBW is used.
Does “IBW” always mean the generic Devine formula?
No. The governing medicine label or protocol can define its own body-weight method. Acyclovir injection labeling gives a medicine-specific example where obese adults are dosed using Ideal Body Weight, while BUSULFEX labeling provides an explicit IBW equation and adjusted-IBW method of its own. The practical rule is simple: use the equation and weight descriptor named by the active source, not whichever IBW calculator happens to be available.
How are IBW and AdjBW different from actual body weight?
Actual body weight is a measurement. IBW and AdjBW are calculated descriptors. They may be useful when a dosing method was developed or validated using that descriptor, but they do not describe the same thing and should not be substituted for one another without a source telling you to do so.
Where does Cockcroft-Gault fit?
Cockcroft-Gault creatinine clearance includes a selected body weight, so choosing actual, ideal or adjusted weight can materially change the CrCl result. The deeper renal-specific weight-selection discussion belongs in the Cockcroft-Gault Guide.
Use the calculators after the method is chosen
Sources
- DailyMed: ZEMDRI (plazomicin) — prescribing information explicitly defining AdjBW = IBW + 0.4 × (TBW − IBW) when TBW is at least 25% above IBW.
- FDA 2024: Pharmacokinetics in Patients with Impaired Renal Function — guidance discussing body-weight approaches with Cockcroft-Gault in overweight and obese individuals.
- DailyMed: Acyclovir Sodium Injection — medicine-specific example using Ideal Body Weight in obese adults.
- DailyMed: BUSULFEX — prescribing information with its own explicit IBW and adjusted-IBW methods.
- UCSF Infectious Diseases Management Program: Dosing Weights.
- Drug dosing in obese adults.
- Weight-based dosing in medication use: what should we know?
- Evaluation of extended-interval aminoglycoside dosing in the morbidly obese population.